Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm. 2010 Jan;117(1):85-96. PubMed Abstract

REAGENTS/MATERIAL:
Two novel antibodies 1-57 and 2-48 against N-terminal truncated Ab starting with pyroglutamate (pGlu, pE) were generated by Synaptic Systems (Goettingen, Germany) http://www.sysy.com/products/pyro-glu/index.php by immunizing three Balb/c mice with a KLH-coupled pyroglutamate- Abeta-peptide with the peptide pEFRHD-C. After preparation of the lymph nodes, cells were fused with the myeloma cell line P3-963-Ag8. The hybridoma supernatants of mixed clones were screened by ELISA and subcloned. The monoclonal antibodies 1-57 (IgG2b) and 2-48 (IgG1) were selected and further characterized for their specificity and affinity. Other monoclonal anti-Ab antibodies used for comparison are 4G8 (Ab epitope 17-24; Covance), HJ5.1 (mouse monoclonal Ab 13-28, courtesy of Hong Jiang and David Holtzman) and Ab[N] (IBL, Hamburg, Germany).